...
首页> 外文期刊>Neurogastroenterology and motility >Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats.
【24h】

Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats.

机译:盐酸乙酰甲酰胺(Z-338)是一种新型的促动力药,可恢复大鼠束缚应激引起的胃排空延迟和进食抑制。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Acotiamide hydrochloride (Z-338) is a member of new class prokinetic agents currently being developed for the treatment of functional dyspepsia (FD). DNA microarray analysis showed that acotiamide altered the expressions of stress-related genes such as gamma-aminobutyric acid (GABA) receptors, GABA transporters and neuromedin U (NmU) in the medulla oblongata or hypothalamus after administration of acotiamide. Therefore, effects of acotiamide on stress-related symptoms, delayed gastric emptying and feeding inhibition, in rats were examined. Acotiamide significantly improved both delayed gastric emptying and feeding inhibition in restraint stress-induced model, but did not affect both basal gastric emptying and feeding in intact rats, indicating that acotiamide exerted effects only on gastric emptying and feeding impaired by the stress. On the other hand, mosapride showed significant acceleration of gastric emptying in intact and restraint stress-induced model, and itopride showed no effect on restraint stress-induced delayed gastric emptying. In addition, gene expression of NmU increased by restraint stress was suppressed by administration of acotiamide, while acotiamide had no effect on delayed gastric emptying induced by an intracerebroventricular administration of NmU, suggesting that the suppressive effect of acotiamide on gene expression of NmU might be important to restore delayed gastric emptying or feeding inhibition induced by restraint stress. These findings suggest that acotiamide might play an important role in regulation of stress response. As stress is considered to be a major contributing factor in the development of FD, the observed effects may be relevant for symptom improvement in FD.
机译:盐酸乙酰胺(Z-338)是目前正在开发的用于治疗功能性消化不良(FD)的新型促运动药的成员。 DNA芯片分析表明,在服用甲酰胺酰胺后,甲酰胺改变了延髓或下丘脑中与应激相关的基因的表达,例如γ-氨基丁酸(GABA)受体,GABA转运蛋白和神经调节素U(NmU)。因此,研究了乙酰甲酰胺对大鼠应激相关症状,胃排空延迟和进食抑制的影响。在约束应激诱导的模型中,乙酰甲酰胺可显着改善延迟的胃排空和进食抑制,但对完整大鼠的基础胃排空和进食均无影响,表明乙酰甲酰胺仅对应激损害的胃排空和进食起作用。另一方面,在完整和约束性应激诱导的模型中,莫沙必利显示出明显的胃排空加速,伊托必利对约束性应激引起的延迟性胃排空没有影响。此外,限制剂量增加的NmU的基因表达被阿考替尼抑制,而阿替酰胺对脑室内施用NmU诱导的胃排空延迟没有影响,这表明阿古替丁对NmU基因表达的抑制作用可能是重要的。恢复因约束压力引起的胃排空延迟或进食抑制。这些发现表明,烟酰胺可能在调节应激反应中起重要作用。由于压力被认为是FD发展的主要因素,因此观察到的效果可能与FD的症状改善有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号